Securing The Pharmaceutical Supply Chain, Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth, Congress, First Session, On Examining Securing the Pharmaceutical Supply Chain, Focusing on How the Food and Drug Administration Faces Challenges Overseeing the Foreign Drug Manufacturing Supply Chain, September 14, 2011 [open pdf - 2MB]
This is the September 14, 2011 hearing, "Securing the Pharmaceutical Supply Chain," before the U.S. Senate Committee Health, Education, Labor and Pensions. From the opening statement of Tom Harkin: "As part of our ongoing process to reauthorize the FDA user fee legislation this congress, we have convened this hearing to examine the safety and integrity of our pharmaceutical supply chain. Few issues are more important to the health and safety of Americans than the integrity of our drug supply. The safety of our medicines has a profound effect on the health and security of our country, and we must have confidence that our system of oversight is up to the task of protecting our families. […] This morning, we will explore systemic concerns associated with the drugs and drug ingredients that are imported into the United States from abroad, and we will learn about the new challenges that both the FDA and American pharmaceutical companies face in navigating the global economy." Statements, letters, and materials submitted for the record include those of the following: Tom Harkin, Deborah Autor, Marcia Crosse, Kendra Martello, Martin VanTrieste, and Allan Coukell.
S. Hrg. 112-866; Senate Hearing 112-866
Government Printing Office: http://www.gpo.gov/